|Scientist profiles G-L|
Sunnybrook Research Institute
Sunnybrook Health Sciences Centre
2075 Bayview Ave., Room FG 53
Administrative Assistant: Vida Jennett
Phone: 416-480-6100, ext. 5328
- BA, 1996, Psychology, University of Pennsylvania, USA
- M.Ed., 1997, Psychology, University of Toronto, Canada
- PhD, 2001, Psychology, University of Toronto, Canada
- MD, 2001, Medicine, University of Calgary, Canada
- FRCPC, 2006, Psychiatry, University of Toronto, Canada
Appointments and Affiliations:
- Scientist, evaluative clinical sciences, Brain Sciences Research Program, Sunnybrook Research Institute
- Academic lead, youth division, department of psychiatry, Sunnybrook Health Sciences Centre
- Assistant professor, departments of psychiatry and pharmacology, faculty of medicine, University of Toronto
- Adjunct assistant professor, Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine
- Adolescent bipolar disorder
- Peripheral biomarkers
- Inflammation and oxidative stress
- Endothelial dysfunction
- Comorbid cardiovascular disease and risk factors
- High-risk offspring studies
Dr. Goldstein's research focuses on bipolar disorder among adolescents. Bipolar disorder is the fourth most disabling medical condition among adolescents worldwide. Adolescent-onset bipolar disorder can often be a particularly severe variant of this illness, underscoring the need for early identification and treatment. To date, assessment and treatment decisions have been guided primarily by subjective factors, and objective biological markers do not yet inform clinical decisions. Bipolar disorder is also associated with greatly increased risk of premature cardiovascular disease; thus far, this association is not well understood.
Dr. Goldstein's research encompasses three aims:
- to identify biomarkers which enhance clinical decision-making for adolescents with bipolar disorder
- to advance the understanding of shared biological factors underlying the links between bipolar disorder and cardiovascular disease
- to examine the impact of novel pharmacological and behavioral treatments on psychiatric and cardiovascular outcomes among youth with bipolar disorder.
The lines of research informed by these three aims offer hope of reduced stigma, earlier identification and improved outcomes for adolescents with bipolar disorder. Dr. Goldstein and his colleagues are pursuing these lines of research with the support of the Canadian Institutes of Health Research, the Depressive and Bipolar Disorder Alternative Treatment Foundation, the Heart and Stroke Foundation of Ontario, the National Institute of Mental Health and generous donations.
See current publications list at PubMed
- Recent progress in understanding pediatric bipolar disorder. Arch Pediatr Adolesc Med. 2012 Apr; 166(4):362–371.
- Preliminary findings regarding proinflammatory markers and brain-derived neurotrophic factor among adolescents with bipolar spectrum disorders. J Child Adolesc Psychopharmacol. 2011 Oct; 21(5):479–484.
- Cardiovascular disease and hypertension among adults with bipolar I disorder in the United States. Bipolar Disord. 2009 Sep; 11(6):657–662.
- Inflammation and the phenomenology, pathophysiology, comorbidity and treatment of bipolar disorder: a systematic review of the literature. J Clin Psychiatry. 2009 Aug; 70(8):1078–1090.
- Preliminary findings regarding overweight and obesity in pediatric bipolar disorder. J Clin Psychiatry. 2008 Dec; 69(12):1953–1959.
Related News and Stories:
- Bipolar Disorder Treatments (February 7, 2012)
- Expert Returns to Tackle Bipolar Disorder in Youth (February 25, 2010)